Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383524003290 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850114175956680704 |
|---|---|
| author | Chunhua Ma Junbiao Chang Bin Yu |
| author_facet | Chunhua Ma Junbiao Chang Bin Yu |
| author_sort | Chunhua Ma |
| collection | DOAJ |
| format | Article |
| id | doaj-art-b31db1ebaabe4b948fa82b99dc5203e6 |
| institution | OA Journals |
| issn | 2211-3835 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj-art-b31db1ebaabe4b948fa82b99dc5203e62025-08-20T02:36:58ZengElsevierActa Pharmaceutica Sinica B2211-38352024-12-0114125512551410.1016/j.apsb.2024.08.009Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infectionChunhua Ma0Junbiao Chang1Bin Yu2State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 453007, ChinaState Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 453007, China; College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University, Zhengzhou 450001, China; Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450000, China; Corresponding authors.College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University, Zhengzhou 450001, China; Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450000, China; Corresponding authors.http://www.sciencedirect.com/science/article/pii/S2211383524003290LenacapavirCapsid inhibitorHIV-1 infectionHIV preventionMultidrug resistanceAntiretroviral medication |
| spellingShingle | Chunhua Ma Junbiao Chang Bin Yu Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection Acta Pharmaceutica Sinica B Lenacapavir Capsid inhibitor HIV-1 infection HIV prevention Multidrug resistance Antiretroviral medication |
| title | Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection |
| title_full | Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection |
| title_fullStr | Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection |
| title_full_unstemmed | Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection |
| title_short | Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection |
| title_sort | sunlenca r lenacapavir a first in class long acting hiv 1 capsid inhibitor for treating highly multidrug resistant hiv 1 infection |
| topic | Lenacapavir Capsid inhibitor HIV-1 infection HIV prevention Multidrug resistance Antiretroviral medication |
| url | http://www.sciencedirect.com/science/article/pii/S2211383524003290 |
| work_keys_str_mv | AT chunhuama sunlencalenacapavirafirstinclasslongactinghiv1capsidinhibitorfortreatinghighlymultidrugresistanthiv1infection AT junbiaochang sunlencalenacapavirafirstinclasslongactinghiv1capsidinhibitorfortreatinghighlymultidrugresistanthiv1infection AT binyu sunlencalenacapavirafirstinclasslongactinghiv1capsidinhibitorfortreatinghighlymultidrugresistanthiv1infection |